Please login to the form below

Not currently logged in
Email:
Password:

tremelimumab,

This page shows the latest tremelimumab, news and features for those working in and with pharma, biotech and healthcare.

Pivotal data sets up Tecentriq filing in small cell lung cancer

Pivotal data sets up Tecentriq filing in small cell lung cancer

inhibitor tremelimumab on top of background chemotherapy in a late-stage trial.

Latest news

More from news
Approximately 5 fully matching, plus 41 partially matching documents found.

Latest Intelligence

  • Pharma deals during July 2014 Pharma deals during July 2014

    tremelimumab. Existing partners Bristol-Myers Squibb (BMS) and Ono Pharmaceutical also announced that they will jointly develop and commercialise multiple immunotherapies as single and combination treatments.

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    2 trials for NSCLC, and tremelimumab, an anti-CTLA4 MAb in phase 2 for the rare cancer mesothelioma. “

  • Pharma deals during August 2013 Pharma deals during August 2013

    The $500m acquisition of Amplimmune marries well with Medimmune's existing commitment to cancer immunotherapy, which includes not only the anti-PD1 mAB MEDI-4736 but also tremelimumab (CLTA-4 mAB)

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics